Log inSign up
Image
user avatar
Kristen Fortney
@kpfortney
CEO and co-founder @bioagelabs developing therapies to extend healthspan and lifespan
Berkeley, CA
bioagelabs.com
Joined July 2017
393
Following
3,426
Followers
  • user avatar
    Kristen Fortney
    @kpfortney
    Sep 30, 2024
    BioAge is now a public company! I'm incredibly proud of our team and grateful to our partners and investors who made this possible. By targeting the biology of aging, we're developing therapies to tackle metabolic diseases and change lives. Excited for what's ahead!
    user avatar
    BioAge
    @bioagelabs
    Sep 30, 2024
    We are thrilled to announce the closing of BioAge's IPO! As of September 26, we are trading on Nasdaq as $BIOA. This milestone will enable our development of novel therapies that treat metabolic diseases by harnessing the biology of aging. (1/3)
    Image
    Image
    Image
    Image
    65K
  • user avatar
    Kristen Fortney
    @kpfortney
    Feb 13, 2024
    Exciting day at BioAge! All made possible by our talented team, visionary investors, and focus on aging science. With our $170M Series D, we're advancing therapies that treat obesity and metabolic diseases to help build a healthier future. Excited for the journey ahead!
    user avatar
    BioAge
    @bioagelabs
    Feb 13, 2024
    BioAge is pleased to announce our $170M Series D financing to advance our therapies for obesity & metabolic diseases. The round was led by Sofinnova, with top-tier healthcare investors including key obesity strategics Lilly & Amgen. businesswire.com/news/home/2024… (🧵 1/8)
    24K
  • user avatar
    Kristen Fortney
    @kpfortney
    Dec 3, 2020
    So excited to announce BioAge’s $90M Series C today and bring our first two therapies to the clinic! Thank you @eladgil and @vijaypande for leading this round and backing our bold mission to develop therapies that extend healthspan and lifespan.
    user avatar
    BioAge
    @bioagelabs
    Dec 3, 2020
    Our $90M Series C will allow us to scale our platform and initiate Phase 2 clinical trials in 2021 for our first two therapies targeting mechanisms of aging
    Image
  • user avatar
    Kristen Fortney
    @kpfortney
    Jul 29, 2024
    Excited to share that we've officially started our Phase 2 trial of azelaprag in combination with tirzepatide for the treatment of obesity. Congratulations to the team at BioAge and our collaborators at Lilly Chorus!
    user avatar
    BioAge
    @bioagelabs
    Jul 29, 2024
    BioAge is pleased to announce initiation of the STRIDES Ph2 clinical trial of azelaprag, an oral exercise mimetic, for obesity—a milestone in our mission to develop new therapies for metabolic diseases by targeting the biology of aging. businesswire.com/news/home/2024… More below! (🧵)
    4.9K
  • user avatar
    Kristen Fortney
    @kpfortney
    Dec 5, 2022
    Excited today to share Ph1b data showing BGE-105's protective effect on muscle atrophy! Target identified from our human data platform, with broad potential to address many diseases of muscle aging. This was a huge effort by our whole team @bioagelabs - congrats all!
    user avatar
    BioAge
    @bioagelabs
    Dec 5, 2022
    BioAge is pleased to announce positive topline Phase 1b data showing that our apelin receptor agonist BGE-105 prevented muscle atrophy in healthy volunteers aged ≥65 years on bed rest. businesswire.com/news/home/2022… Keep reading to learn why we’re so excited about this. (🧵 1/6)
  • user avatar
    Kristen Fortney
    @kpfortney
    Feb 26, 2021
    BioAge’s first clinical trial EVER started today! So excited for this amazing milestone. Many more to come as we advance our mission to develop a pipeline of therapies that treat disease and extend healthspan.
    user avatar
    BioAge
    @bioagelabs
    Feb 26, 2021
    BioAge’s first clinical trial of BGE-117 is now underway. This Ph2a trial will evaluate the efficacy of BGE-117 for unexplained anemia of aging (UAA), and in addition collect data on aging biomarkers and exploratory muscle aging endpoints. bioagelabs.com/BGE-117_Phase_…
    Image
  • user avatar
    Kristen Fortney
    @kpfortney
    Oct 26, 2023
    Thrilled to partner with the expert team at Lilly Chorus on our obesity Ph2! Our oral drug azelaprag, combined with an incretin drug, has the potential to improve weight loss quantity and quality. Tackling obesity can help cut the population burden of age-related disease.
    user avatar
    BioAge
    @bioagelabs
    Oct 26, 2023
    We are pleased to announce plans to initiate a Ph2 trial of our drug azelaprag co-administered with tirzepatide for treatment of obesity, in collaboration with @EliLillyandCo's Chorus organization, to start in mid-2024. businesswire.com/news/home/2023… Keep reading to learn more (🧵1/7)
    12K
  • user avatar
    Kristen Fortney
    @kpfortney
    Mar 21, 2022
    BioAge’s collaboration on our Ph2 immune aging drug BGE-175 / asapiprant is out today in @Nature!! This was a huge effort from our brilliant collaborators from the Perlman and McCray labs at @IowaMed and scientific team at @bioagelabs (1/3)
    user avatar
    BioAge
    @bioagelabs
    Mar 21, 2022
    Today in @Nature: New study shows @bioagelabs’ investigational drug BGE-175/asapiprant protects aged mice from COVID-19 lethality by reversing immune aging. BGE-175 is now in Phase 2 trials in older patients hospitalized with COVID-19. Release: businesswire.com/news/home/2022… 🧵(1/8)
    Image
  • user avatar
    Kristen Fortney
    @kpfortney
    May 10, 2023
    I’m thrilled and honored to be selected by @FiercePharma alongside an amazing group of healthcare leaders. It’s wonderful recognition for the great science being done by the team at @bioagelabs.
    user avatar
    BioAge
    @bioagelabs
    May 10, 2023
    Our CEO and co-founder @kpfortney is one of @Fiercepharma’s 2023 “Most Influential People in Biopharma"! Read more about how we’re translating insights from healthy longevity into innovative therapies to treat age-related disease. fiercepharma.com/special-report…
    4.5K
  • user avatar
    Kristen Fortney
    @kpfortney
    Apr 19, 2022
    So excited to launch our first clinical trial of BGE-105! Very promising mechanism with broad potential for muscle aging
    user avatar
    BioAge
    @bioagelabs
    Apr 19, 2022
    New Phase 1b study! BioAge's apelin receptor agonist BGE-105 has the potential to treat multiple acute & chronic conditions driven by muscle aging. We will collect biomarker data to inform Ph2 trial design for muscle atrophy in hospitalized patients. businesswire.com/news/home/2022…
  • user avatar
    Kristen Fortney
    @kpfortney
    Jan 24, 2019
    I'm thrilled to announce today that BIOAGE has raised $23M! link.medium.com/PfOy7C15JT
  • user avatar
    Kristen Fortney
    @kpfortney
    Jul 5, 2021
    Powerful economic argument for targeting aging published today @NatureAging. "...A slowdown in aging that increases life expectancy by 1 year is worth US$38 trillion, and by 10 years, US$367 trillion." !!!! Great work @ProfAndrewScott @davidasinclair
    user avatar
    David Sinclair
    @davidasinclair
    Jul 5, 2021
    Our new paper calculates the value to the US economy of widely prescribing Metformin, a cheap medicine that could extend lifespan by >2.6 years, is at least $38 trillion dollars. Let’s take that to the bank! @NatureAging tinyurl.com/r56w96ze
    Image
  • user avatar
    Kristen Fortney
    @kpfortney
    Apr 14, 2021
    BioAge is bringing in a promising drug from Amgen! BGE-105 is an agonist of the APJ receptor, and we will take it into Ph1 in Q1’22. This is BioAge’s third clinical-stage drug candidate targeting an important mechanism of aging.
    user avatar
    BioAge
    @bioagelabs
    Apr 14, 2021
    BioAge has signed an exclusive license agreement with Amgen to develop and commercialize BGE-105, Amgen’s Ph1 oral APJ agonist. BioAge human platform data and promising preclinical results show BGE-105 may help treat diseases driven by muscle aging. businesswire.com/news/home/2021…
    Image
  • user avatar
    Kristen Fortney
    @kpfortney
    Oct 8, 2020
    Our focus at @bioagelabs is on mapping human aging to develop therapies that treat disease and extend healthspan. Super excited to share some thoughts on why understanding aging will be the key to curing many highly morbid diseases like Alzheimer's. Thanks @vijaypande @a16z
    user avatar
    a16z
    @a16z
    Oct 7, 2020
    The connection between the aging process & certain diseases like Alzheimer's may be the key to unlocking our understanding & treatment of them, say @vijaypande & @kpfortney. Examining age as a root cause will guide us to the medicines of the future: bit.ly/agingandalzhei…